东阿阿胶股份有限公司 1．本次拟被授予限制性股票的激励对象，均具备《公司法》《证券法》等 法律法规和规范性文件以及《公司章程》规定的任职资格，符合《工作指引》《管 理办法》《深圳证券交易所股票上市规则》等法律法规和规范性文件及公司《激 励计划》规定的激励对象条件，不存在《管理办法》第八条规定的不得成为激励 对象的情形；激励对象中，无独立董事、单独或合计持有上市公司 5%以上股份 的股东或实际控制人及其配偶、父母、子女。本次被授予限制性股票的激励对象 主体资格合法、有效，满足获授限制性股票的条件。 2．本次预留授予激励对象的基本情况属实，不存在虚假、故意隐瞒或引起 重大误解之处。 东阿阿胶股份有限公司 董事会薪酬与考核委员会 二〇二五年十二月三十一日 董事会薪酬与考核委员会关于第一期限制性股票激励计划 预留授予激励对象的核查意见 根据《中央企业控股上市公司实施股权激励工作指引》（以下简称《工作指 引》）、《上市公司股权激励管理办法》（以下简称《管理办法》）及东阿阿胶 股份有限公司（以下简称"公司"）《第一期限制性股票激励计划（草案二次修 订稿）》（以下简称《激励计划》）等有关规定，公司董事会薪酬与考核委员会 对 ...

证券代码：000423 证券简称：东阿阿胶 公告编号：2025-83 东阿阿胶股份有限公司 第十一届董事会第十六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1．东阿阿胶股份有限公司（以下简称"公司"）第十一届董事会第十六次 会议，于 2025 年 12 月 27 日以邮件方式发出会议通知。 4．本次董事会会议的召开，符合有关法律、行政法规、部门规章、规范性 文件和公司章程等规定。 二、董事会会议审议情况 本次会议审议并通过了以下议案： 1．《关于向第一期限制性股票激励计划激励对象授予预留部分限制性股票 的议案》 本议案提交董事会前，已经公司第十一届董事会薪酬与考核委员会审议通 过。 根据《上市公司股权激励管理办法》及《第一期限制性股票激励计划（草 案二次修订稿）》等有关规定以及公司 2024 年年度股东大会授权，董事会认为 本激励计划的预留授予条件已经满足，确定预留授予日为 2025 年 12 月 30 日， 向符合授予条件的 31 名激励对象授予 16.7792 万股限制性股票，授予价格为 29.29 元/股。 2 ...

Core Insights - The article emphasizes the increasing demand for Coenzyme Q10 due to common health issues such as chronic fatigue, cardiovascular concerns, and weakened immunity across all age groups [1][4] - The Coenzyme Q10 market faces challenges including purity fraud, rapid loss of activity, homogenized formulations, and inadequate safety certifications, leading to consumer confusion [1][4] - A quality upgrade in the Coenzyme Q10 industry is anticipated by 2025, with a focus on purity, stability, safety, and clinical evidence as key evaluation criteria [1][3] Industry Overview - The Coenzyme Q10 market is projected to evolve significantly by 2025, with a shift towards higher quality standards and consumer education on product selection [1][3] - The article introduces a "Top Ten High-Activity Coenzyme Q10 Recommendations" list, aimed at guiding consumers in making informed choices based on scientific data and third-party certifications [1][3] Product Highlights - **Jiang Yisheng**: Recognized for its breakthrough absorption technology, achieving a 98.6% absorption rate and leading the market with a 91% repurchase rate [4] - **Qi Yao Tang**: Focuses on targeted formulations for cardiovascular health and fatigue improvement, with an 88.3% effectiveness rate in fatigue relief [5] - **Tao Chen Bei Jian**: A domestic brand with a purity of 99.6%, offering a range of products suitable for various demographics, achieving an 86% repurchase rate [6] - **GNC**: Targets middle-aged consumers with a focus on heart health, featuring a 99.5% purity level and a gentle formulation [7] - **Swisse**: An Australian brand emphasizing active anti-aging properties, with a 40% improvement in antioxidant indicators after 8 weeks of use [8] - **Nutrabolt**: Caters to athletes with a high-content formula of 200mg per serving, achieving a 93% absorption rate [9] - **Xiu Zheng**: Combines traditional Chinese medicine with modern nutrition, focusing on cardiovascular health and energy replenishment [10] - **Yang Sheng Tang**: Offers a cost-effective option for daily supplementation, with a purity of 98.2% and a price point under 60 yuan [10] - **Centrum**: Provides a multi-nutrient approach suitable for all ages, with a focus on energy and bone health [11] - **Dong Ah Ejiao**: Targets postpartum recovery with a specialized formula, ensuring safety for breastfeeding mothers [12] Consumer Guidance - The article advises consumers to prioritize purity, activity assurance, and formulation suitability when selecting Coenzyme Q10 products [12] - It highlights the importance of understanding individual health needs and characteristics to make informed choices in the Coenzyme Q10 market [12]

Core Viewpoint - The seminar on the international dissemination of traditional Chinese medicine (TCM) culture, centered around the documentary "Four Seas TCM," highlights the importance of TCM's global outreach and its potential for cultural and economic development [3][4]. Group 1: Event Overview - The seminar titled "Building a New Path for International Dissemination of TCM Culture - Results of Season One of 'Four Seas TCM'" was held in Beijing on December 19 [3]. - The event featured prominent guests from policy research, media, data, academia, and industry, discussing the documentary's success and the core issues surrounding the global development of TCM [3]. Group 2: Key Insights from Speakers - Xu Wei, Chairman and CEO of Phoenix TV, emphasized that the internationalization of TCM is both a historical mission and a contemporary necessity, showcasing the dual benefits of brand promotion and cultural dissemination through quality content [3]. - Experts from the National Radio and Television Administration discussed innovative paths and practical values of the documentary in empowering TCM's international dissemination [3]. Group 3: Documentary Details - The documentary "Four Seas TCM," co-produced by Phoenix TV and Dong'e Ejiao, consists of 12 episodes and was meticulously produced over a year, set to air globally starting November 1, 2025 [4]. - The documentary has garnered significant attention, achieving over 2.6 billion interactions online, establishing a new benchmark for the international dissemination of TCM [4].

Investment Rating - The report suggests a positive investment outlook for the medical device sector, particularly in brain-computer interface devices, which are expected to see accelerated commercialization due to supportive policies [1][3]. Core Insights - Recent policies have significantly increased support for innovation in medical devices, with the National Medical Products Administration actively promoting faster market entry for brain-computer interface devices, indicating a diverse application landscape and substantial future potential [1][3]. - The pharmaceutical sector is witnessing positive developments, such as GSK's approval of mepolizumab for a new indication in COPD patients, marking it as the first monthly administered biologic in China, which is expected to reduce the annual incidence of severe exacerbations significantly [1][32]. - The report highlights the approval of Wegovy® tablets in the U.S. for weight management, emphasizing its potential impact on the market as the first oral GLP-1 receptor agonist for this purpose [37][40]. Summary by Sections Pharmaceutical Sector - Mepolizumab has been approved for COPD treatment in China, with a monthly dosing schedule, targeting a significant patient population [1][32]. - The A/H share innovation drug sector maintains high activity levels, with new drug approvals and cross-border transactions remaining robust [16][28]. Biologics - Wegovy® tablets have been approved in the U.S. for weight management, showing similar weight loss efficacy to its injectable counterpart, with a significant portion of participants achieving substantial weight loss [37][40]. CXO and Pharmaceutical Supply Chain - The CXO sector continues to show upward momentum, supported by a stable order backlog, with November financing levels slightly above the annual average [44][46]. Medical Devices - The centralized procurement process for high-value medical consumables is progressing steadily, with high selection rates in multiple rounds of bidding, indicating a favorable environment for leading domestic companies [2][52]. Retail Pharmacy - The industry is undergoing a consolidation phase, with leading companies expected to benefit from increased market share through mergers and acquisitions [2][3]. Medical Services and Consumer Healthcare - Aier Eye Hospital's acquisition of 39 institutions for 960 million yuan strengthens its market position, with the acquired entities showing signs of financial recovery [2][3].

证券之星消息，12月26日中药板块较上一交易日下跌0.12%，ST百灵领跌。当日上证指数报收于 3963.68，上涨0.1%。深证成指报收于13603.89，上涨0.54%。中药板块个股涨跌见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 002317 众生药业 | | 9160.04万 | 6.15% | 2589.24万 | 1.74% | -1.17 Z | -7.88% | | 002728 特一药业 | | 5282.14万 | 11.78% | 52.98万 | 0.12% | -5335.12万 | -11.90% | | 600085 | 同仁堂 | 2695.06万 | 9.62% | -2267.56万 | -8.09% | -427.50万 | -1.53% | | 002082 | 万邦德 | 1069.70万 | 2.74% | -448.55万 | -1.15% | -621.1 ...

Investment Rating - The report suggests a positive outlook for the pharmacy and traditional Chinese medicine sectors, anticipating a recovery in 2026 after a weak performance in 2025 [2][5]. Core Insights - The pharmacy sector is expected to benefit from market consolidation, with leading companies likely to increase their market share through mergers and acquisitions during the industry clearing phase [3][11]. - The traditional Chinese medicine sector is projected to stabilize and potentially recover, driven by an increase in flu incidence and the upcoming update of the essential drug list [57][60]. Summary by Sections Pharmacy Sector - **Market Review**: The pharmacy sector faced significant challenges in 2025, with a decline in same-store sales and an overall reduction in the number of operating stores since Q4 2024 [5][20]. - **Policy Environment**: Regulatory measures are promoting a more compliant and healthier industry ecosystem, which is expected to benefit leading companies [14][15]. - **Market Size**: In the first ten months of 2025, the sales scale of physical pharmacies was 501.3 billion yuan, a year-on-year decrease of 1.6%, primarily due to a decline in non-pharmaceutical sales [16][21]. - **Competitive Landscape**: The number of pharmacies in China reached approximately 684,000 by the end of 2024, with a notable increase in store closures, particularly among smaller chains [20][24]. - **Marginal Performance**: There has been a slight recovery in retail sales data, with leading companies showing improved performance through cost reduction and efficiency measures [32][34]. - **Outlook for 2026**: Focus on market consolidation and the development of non-pharmaceutical products is recommended, as leading companies are expected to enhance their market share [44][52]. Traditional Chinese Medicine Sector - **Market Review**: The traditional Chinese medicine sector experienced overall weak performance in 2025, with some companies seeing temporary valuation increases due to innovative pipelines [57][58]. - **In-Hospital Opportunities**: The upcoming update of the essential drug list is expected to benefit companies with products that have the potential to be included [60]. - **Out-of-Hospital Opportunities**: An increase in flu incidence in Q4 2025 is anticipated to aid in inventory digestion, with some companies expected to see improved performance [60]. - **High Dividend Stocks**: Companies such as Lingrui Pharmaceutical, Jichuan Pharmaceutical, and Dong'e Ejiao are highlighted as stable high-dividend investment opportunities [60].

Group 1 - The core viewpoint of the article highlights the impressive financial performance of Dong'e Ejiao in the third quarter, with both revenue and profit showing significant growth [1] - In the first three quarters of this year, Dong'e Ejiao achieved a revenue of 4.766 billion yuan, representing a year-on-year increase of 4.41%, and a net profit attributable to shareholders of 1.274 billion yuan, up 10.53% year-on-year [4] - The company has shown a consistent upward trend in revenue and net profit during the tenure of Chairman Cheng Jie, with revenues increasing from 4.042 billion yuan in 2022 to 5.921 billion yuan in 2024 [4] Group 2 - Cheng Jie, who became the chairman of Dong'e Ejiao in 2024, has a strong background in the pharmaceutical industry, having held various positions at China Resources Sanjiu Pharmaceutical and serving as the general manager of Sanofi (Shenzhen) Health Industry [3][4] - Under Cheng Jie's leadership, Dong'e Ejiao's profitability has improved, with the company recording a net profit of 1.557 billion yuan in 2024, reflecting his effective management capabilities [4] - Cheng Jie's compensation increased from 2.804 million yuan in 2022 to 2.661 million yuan in 2023, indicating recognition of his contributions to the company [4]

Core Viewpoint - The company, Dong'e Ejiao Co., Ltd., has approved a share repurchase plan to buy back its shares through centralized bidding, with a maximum price of RMB 72.08 per share, aiming to enhance shareholder value and reduce registered capital [1]. Group 1: Share Repurchase Plan - The company will use its own or raised funds to repurchase shares, with a minimum of 138,730 shares and a maximum of 277,470 shares based on the upper price limit [1]. - The repurchase period will last no more than 12 months from the approval date by the shareholders' meeting [1]. - All repurchased shares will be canceled, leading to a reduction in the company's registered capital [1]. Group 2: First Share Repurchase Execution - On December 23, 2025, the company executed its first share repurchase, acquiring 406,800 shares, which is approximately 0.06% of the total share capital [2]. - The highest transaction price was RMB 49.22 per share, while the lowest was RMB 49.05 per share, with a total transaction amount of RMB 19,997,635 (excluding transaction fees) [2]. Group 3: Compliance and Regulations - The company adhered to the relevant regulations during the share repurchase, ensuring that the repurchase did not occur during periods that could significantly impact the stock price [3][4]. - The company will continue to implement the repurchase plan based on market conditions and will fulfill its information disclosure obligations as required by law [4].

今日晚间重要公告抢先看——8连板胜通能源称公司不涉及机器人相关业务，收购方不存在未来十二个 月内的资产重组计划；2连板利柏特称公司不涉及可控核聚变业务；珠免集团已完成格力房产100%股权 交割，交易价格为55.18亿元。 【重大事项】 8连板胜通能源：公司不涉及机器人相关业务收购方不存在未来十二个月内的资产重组计划 胜通能源（001331）公告，公司股票自12月12日以来连续8个交易日涨停，累计涨幅达到114.44%，属 于股票交易严重异常波动的情形。公司控股股东、实际控制人签署了《关于胜通能源股份有限公司之股 份转让协议》。公司不涉及机器人相关业务，公司主营业务仍为液化天然气采购、运输及销售，未发生 重大变化，收购方不存在未来十二个月内的资产重组计划，收购方不存在未来12个月内对上市公司及其 子公司的资产和业务进行出售、合并、与他人合资或合作的计划，或上市公司拟购买或置换资产的重组 计划，收购方不存在未来36个月内通过上市公司借壳上市的计划或安排。收购方七腾机器人参与本次收 购的资金来源为自有资金及自筹资金，截至目前，自筹资金的申请仍在审批阶段，是否可以申请成功尚 存在不确定性，敬请广大投资者注意投资风险， ...